JAAD CME第二部分:GLP-1受体激动剂在皮肤科的临床证据与安全性考量
本文综述GLP-1受体激动剂(GLP-1RAs)在皮肤科应用的早期临床证据,主要来自病例报告、小队列和短期试验,提示其可能改善银屑病和化脓性汗腺炎(HS)等慢性炎症性皮肤病,并在观察性研究中与伤口愈合终点改善相关。但证据受小样本、药物/剂量异质性和合并症混杂限制,需更大型长期随机试验明确疗效、机制和安全性。
要点
- 早期证据提示GLP-1RAs可能改善银屑病和HS的疾病活动度及患者报告症状。
- 观察性研究显示GLP-1RAs可能与伤口愈合并发症减少相关。
- 需警惕胃肠道不耐受、胆道疾病、视网膜病变风险及皮肤不良反应如瘙痒、药疹、脱发和痤疮。
核心结论
- 早期临床证据提示GLP-1RAs可能改善慢性炎症性皮肤病(尤其银屑病和HS)结局,并可能与伤口愈合终点改善相关,但证据有限,需大型长期随机试验验证。
研究设计与样本
- 本文为综述,汇总的早期临床证据主要来自病例报告、小队列研究和短期试验,以及观察性研究和回顾性数据集。
主要发现
- 报告获益包括银屑病面积与严重度指数评分降低、HS疾病活动度和患者报告症状改善,以及回顾性数据集中伤口并发症减少。
- 效应可能反映直接免疫调节和间接代谢获益(体重减轻和全身炎症减少)。
- 证据受小样本、药物/剂量异质性和合并糖尿病/肥胖及 concurrent therapies 的混杂限制。
临床怎么用
- 临床医生应考虑GLP-1RAs的系统性和皮肤不良事件,包括胃肠道不耐受、胆道疾病、快速血糖改善相关的视网膜病变风险及皮肤反应(如瘙痒、药疹、脱发、痤疮)。
局限性
- 证据主要来自病例报告、小队列和短期试验,样本量小,药物和剂量异质性大,且存在合并症和合并治疗的混杂。
- 需要更大规模、更长期的随机试验来确定皮肤科适应症的疗效、机制和安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have revolutionized the treatment of type 2 diabetes mellitus and obesity by improving glycemic control, reducing body weight, and lowering cardiometabolic risk. Beyond their metabolic effects, GLP-1RAs may exert anti-inflammatory and immunomodulatory effects, spurring investigation into dermatologic applications. Early clinical evidence, largely case reports, small cohorts, and short-duration trials, suggest GLP-1RAs may improve outcomes in chronic inflammatory skin disease, particularly psoriasis and hidradenitis suppurativa (HS), and may be associated with improved wound-healing endpoints in observational studies. Reported benefits include reductions in Psoriasis Area and Severity Index scores, improved HS disease activity and patient-reported symptoms, and fewer wound complications in retrospective datasets; effects may reflect both direct immunomodulation and indirect metabolic benefits (weight loss and reduced systemic inflammation). However, evidence remains limited by small samples, heterogeneity in agents/dosing, and confounding by comorbid diabetes/obesity and concurrent therapies. Clinicians must also consider systemic and cutaneous adverse events, including gastrointestinal intolerance, biliary disease, retinopathy risk with rapid glycemic improvement, and dermatologic reactions (e.g., pruritus, drug eruptions, alopecia, acne). Larger, longer-term randomized trials are needed to define efficacy, mechanisms, and safety in dermatologic indications.
引用
- Narla S, Narla RR. JAAD CME Part 2: Clinical Evidence and Safety Considerations for GLP-1 Receptor Agonists in Dermatology. J Am Acad Dermatol. 2026. PMID: 41698604. doi:10.1016/j.jaad.2025.12.116
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。